Looking for early warning signs of lung inflammation from cancer treatment
Part of Cancer, Lungs & breathing clinical trials.
This study looks for early signs of lung inflammation (pneumonia) that can be caused by cancer treatments. By collecting samples from your lungs and blood before and during treatment, researchers hope to find markers that predict who might get this side effect, so it can be caught and treated earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You will be starting a new cancer treatment (like chemotherapy or immunotherapy) soon
- You must be willing to have a bronchoscopy (a procedure to collect fluid from your lungs) at the start of treatment
- You must not have an active infection or other lung condition not caused by your cancer treatment
- You must not be taking high-dose steroids or immune-suppressing medications right now
- You must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
This study uses a fluid sample taken from your lungs (called bronchoalveolar lavage) to understand the specific types of inflammation in different forms of interstitial lung disease. This may help doctors tailor better treatments for you in the future.
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This Phase 1/2 study uses detailed “single-cell” testing (from lung samples) to better understand why lung inflammation happens after cancer radiation or immunotherapy. It aims to help choose the right treatment approach for people with radiation pneumonitis or immune checkpoint inhibitor pneumonitis.
Hear when a new Anti-Tumor Drug-Associated Interstitial Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.